Cite
HARVARD Citation
Metzger, M. et al. (n.d.). SAFETY AND RESPONSE AFTER 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL). Hematological oncology. pp. 55-56. [Online].